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Abstract
Background: The genetic and molecular mechanisms responsible for and associated with the development and
progression of prostate malignancy are largely unidentified. The peripheral zone is the major region of the human
prostate gland where malignancy develops. The normal peripheral zone glandular epithelium has the unique
function of accumulating high levels of zinc. In contrast, the ability to accumulate zinc is lost in the malignant cells.
The lost ability of the neoplastic epithelial cells to accumulate zinc is a consistent factor in their development of
malignancy. Recent studies identified ZIP1 (SLC39A1) as an important zinc transporter involved in zinc
accumulation in prostate cells. Therefore, we investigated the possibility that down-regulation of hZIP1 gene
expression might be involved in the inability of malignant prostate cells to accumulate zinc. To address this issue,
the expression of hZIP1 and the depletion of zinc in malignant versus non-malignant prostate glands of prostate
cancer tissue sections were analyzed. hZIP1 expression was also determined in malignant prostate cell lines.
Results: hZIP1 gene expression, ZIP1 transporter protein, and cellular zinc were prominent in normal peripheral
zone glandular epithelium and in benign hyperplastic glands (also zinc accumulating glands). In contrast, hZIP1 gene
expression and transporter protein were markedly down-regulated and zinc was depleted in adenocarcinomatous
glands and in prostate intra-epithelial neoplastic foci (PIN). These changes occur early in malignancy and are
sustained during its progression in the peripheral zone. hZIP1 is also expressed in the malignant cell lines LNCaP,
PC-3, DU-145; and in the nonmalignant cell lines HPr-1 and BPH-1.
Conclusion: The studies clearly establish that hZIP1 gene expression is down regulated and zinc is depleted in
adenocarcinomatous glands. The fact that all the malignant cell lines express hZIP1 indicates that the down-
regulation in adenocarcinomatous glands is likely due to in situ gene silencing. These observations, coupled with
the numerous and consistent reports of loss of zinc accumulation in malignant cells in prostate cancer, lead to the
plausible proposal that down regulation of hZIP1 is a critical early event in the development prostate cancer.
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Background
Despite the extensive clinical and experimental studies
over the recent decades, the pathogenesis of prostate can-
cer remains unknown. The genetic and molecular mecha-
nisms responsible for and associated with the
development of malignant prostate cells and their pro-
gression are largely unidentified [for reviews see [1,2]].
The major site for the development of prostate malig-
nancy is the peripheral zone, which comprises about 70%
of the prostate gland. It is well established that the normal
peripheral zone has the function of accumulating
extremely high zinc levels that are 3–10-fold greater than
found in other soft tissues [3]. This capability resides in
the highly specialized glandular secretory epithelial cells
of the peripheral zone, which we characterize as "zinc-
accumulating" cells. In contrast, the malignant prostate
cells that develop in the peripheral zone do not contain
the high zinc levels that characterize the normal secretory
epithelial cells. Repeated studies consistently show that
the zinc levels of malignant prostate tissue are 62–75%
lower than the normal prostate tissue [4-8]. Measure-
ments of pure malignant tissue in the absence of normal
glandular epithelium would reveal even lower zinc levels
that would approximate the levels found in other soft tis-
sues. This consistency persists in different reports by dif-
ferent investigators employing different populations and
tissue samples and involving various stages of malig-
nancy. The studies of Zaichick et al [9] and Vartsky et al
[10] further reveal the critically important relationship
that, in individual analyses, malignant prostate tissue
never exhibits high zinc levels. In addition, Habib [11]
reported that the decrease in zinc occurs early in malig-
nancy. These persistent results, and the additional corrob-
orating evidence presented below, firmly establish that
the unique zinc-accumulating capability of the normal
peripheral zone secretory epithelial cells is lost in the neo-
plastic transformation to malignant cells; and that zinc-
accumulating malignant cells do not exist in situ in pros-
tate cancer. For extensive presentations of the relation-
ships of zinc in normal prostate and prostate cancer, we
refer the reader to our recent reviews [12-14].
Established clinical and experimental evidence provides
the basis for our concept that zinc accumulation prevents
the malignant activities of the neoplastic prostate cell; and
that impaired zinc accumulation is an essential require-
ment for the manifestation of prostate malignancy. If such
is the case, one should expect that the zinc-accumulating
process that characterizes the normal glandular epithe-
lium is absent or defective in the malignant cells. Until
recently, no information had been available regarding the
mechanism(s) of zinc accumulation in prostate cells.
Recent studies [15-17] have established that the zinc
uptake transporter, ZIP1, is important in the uptake and
accumulation of zinc by prostate cells. Up-regulation of
ZIP1 in prostate cells increases zinc accumulation; and,
correspondingly, down-regulation of ZIP1 decreases zinc
accumulation in prostate cells. In addition, Rishi et al [18]
reported that ZIP1 (and ZIP2) expression in peripheral
zone glandular epithelium of black males is down regu-
lated when compared to its expression in white males;
which coincides with the race-associated higher incidence
of prostate cancer in African-Americans. These relation-
ships suggested that the decrease in zinc in malignant
prostate glands might be due to the down regulation of
ZIP1 expression. In this report we show, for the first time,
the down regulation of hZIP1 gene expression, the loss of
ZIP1 transporter protein and the depletion of zinc that is
evident in malignant prostate glands. The evidence pre-
sented supports the likelihood that down regulation of
ZIP1 gene expression in the neoplastic prostate cell is an
essential step in the development of prostate malignancy.
The studies were conducted independently at three differ-
ent institutions, which strengthens the validity of these
corroborating results.
Results
The studies presented in this report were conducted at the
University of Maryland (UMaryland study), the Roswell
Park Cancer Institute (Roswell Park Study), and Claflin
University (ClaflinU study). Therefore the results will be
presented as provided by each separate and independent
study, followed by the discussion of the evidence and sup-
porting basis for the genetic/metabolic concept of the role
of zinc in prostate malignancy.
The UMaryland Study (RBF, PF, BM, LCC)
Earlier studies [15-17] demonstrated that ZIP1 is
expressed in malignant prostate cell lines (PC-3 and
LNCaP cells); and that this zinc uptake transporter func-
tions in the uptake and cellular accumulation of zinc. This
caused us to initiate preliminary studies to determine if
ZIP1 gene expression and/or the level of the transporter
protein might be down-regulated in malignant prostate
glands in comparison to the expression in normal pros-
tate glandular epithelium. Paraffin mounted serial sec-
tions of human prostate tissue were used for ZIP1
immumohistochemistry staining. Hematoxylin and eosin
staining was used for pathologic evaluation of normal
glands and adencarcinomatous foci. Figure 1A reveals the
membrane-associated immunohistochemical identifica-
tion of ZIP1 in the normal peripheral zone glandular epi-
thelium. In contrast, the malignant glands were
essentially devoid of demonstrable membrane-associated
ZIP1. It is also apparent that ZIP1 is confined to glandular
epithelium and is not demonstrable in the stromal tissue.
Figure 1B presents RT-PCR analysis of ZIP1 expression in
tissue extracts of malignant tissue versus benign hyper-
plastic (BPH) glands; which, like normal peripheral zone,
are zinc-accumulating glands. The results demonstrate aMolecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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relatively high level of ZIP1 gene expression in BPH glan-
dular tissue as compared with a barely detectable expres-
sion level in malignant tissue. These results provided the
initial preliminary evidence that indicated that down reg-
ulation of ZIP1 expression is associated with malignant
prostate tissue.
We previously reported the identification by Western blot
of the presence of ZIP1 in PC-3 and LNCaP cells under
standard culture conditions. These are malignant cell lines
that were derived from metastatic prostate tissue. For cor-
relation with the human tissue results, we proceeded to
determine the presence of ZIP1 transporter in these cells
by immunocytochemistry. Figure 1C shows the localiza-
tion of ZIP1 in the plasma membrane; which is similar to
the localization in normal peripheral zone glandular epi-
thelium. The retention of this gene expression in LNCaP,
PC-3, and DU145 (not shown) cells demonstrates that the
absence of ZIP1 expression in the malignant glands in situ
is not due to the deletion or fatal mutation of the gene. No
information exists regarding ZIP1 in metastatic cells in
situ in prostate cancer. However, it seems most improba-
ble that the gene would re-appear in metastasis, unless it
was reversibly down-regulated in the primary site malig-
nant glands. Therefore the results strongly implicate the
epigenetic silencing of hZIP1 gene expression in the pri-
mary site malignant cells under the in situ environmental
conditions of the malignant prostate gland.
These initial observations dictated the importance of
expanding the clinical investigation to establish conclu-
sively that ZIP1 is down regulated in prostate malignancy
and is associated with a decrease in zinc accumulation in
the malignant cells. To achieve this, independent studies
were conducted at Roswell Park Cancer Institute and at
Claflin University without prior knowledge of the results
of the UMaryland study.
2. The Roswell Park Study (MMD, KKS)
The Roswell Park (RPCI) resources provided the opportu-
nity to conduct ZIP1 immunohistochemical analysis of
prostatic adenocarcinoma slides without identification
related to patients. Twenty-two cases of prostatic adeno-
carcinoma were obtained from RPCI that contained both
adenocarcinomatous foci and adjacent benign prostatic
hyperplasia (table 1). Four of the cases contained normal
prostatic glands and five cases contained prostatic intra
epithelial neoplastic foci (PIN). The tumors were graded
according to the World Health Organization grading sys-
tem [19]. Grade 1 is defined by well differentiated glands
with minimal anaplasia in which the nuclei are almost
uniform with minimal variation in size and shape, and
few detectable nucleoli. Grade 2 is defined by moderately
differentiated glands with moderate nuclear anaplasia
with many nucleoli. Grade 3 is defined by poorly differen-
tiated or undifferentiated glands showing marked anapla-
sia in which the nuclei showed marked variation in size
(A) Immunohistochemical determination of ZIP 1 trans- porter levels in normal and malignant prostate glands Figure 1
(A) Immunohistochemical determination of ZIP 1 trans-
porter levels in normal and malignant prostate glands. The 
strong positive reaction is evident in the normal gland secre-
tory epithelial cells that border the lumen, and is virtually 
absent in the malignant glands. Note that ZIP1 is not appar-
ent in the stroma. (B) RT-PCR of RNA extracted from 
malignant prostate tissue and benign prostatic hyperplasia. 
Note the marked decrease in ZIP1 mRNA in the malignant 
tissue. Results are representative of two independent sam-
ples. Density of the bands was determined by densitometry 
scans and GAPDH band intensity used to normalize hZIP1 
mRNA. hZIP1/GAPDH for PCa and BPH were 0.71 ± 0.067 
and 1.02 ± 0.092 respectively. (C) Immunohistochemical 
detection of ZIP1 in malignant prostate cell lines. Note the 
association of ZIP1 with the plasma membrane.Molecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
Page 4 of 13
(page number not for citation purposes)
and irregular shapes, vesicular, with marked abnormal
mitotic figures.
Figure 2 shows the representative results of the ZIP1
immunohistochemical staining observed in normal
peripheral zone glands, BPH glands, adenocarcinomatous
glands and in PIN. The glandular epithelium of the nor-
mal glands and BPH glands (both being zinc-accumulat-
ing glands) exhibit immuno-positive ZIP1 staining that is
localized predominantly at the basolateral membrane. In
contrast, in the adenocarcinomatous glands and PIN,
ZIP1 is negligible in the malignant cells so that the
appearance of cell membranes is essentially absent. It is
also evident that ZIP1 transporter is not detected in the
stromal tissue, which corroborates the results of the
U.Maryland preliminary study.
Table 1 is the summary of the immunohistochemical scor-
ing of hZIP1 reactivity of tissue sections from 22 cases of
prostate cancer. The analysis involves the comparison of
ZIP1 in glands located in the same tissue section. This
eliminates, or at least minimizes, any potential technical
differences arising from antibody diffusion into the tissue
sections and cells for immuno-reactivity. Any comparative
differences observed in the immuno-reactivity in the dif-
ferent glands of the same tissue slice would be due to com-
parative differences in the level of hZIP1. Analysis of the
22 cases (figure 3) for the presence of glands that exhibit
ZIP1 immuno-positivity results in a significant difference
(P < 0.01) between BPH glands (19 positive/3 negative)
and adenocarcinomatous glands (7 positive/15 negative).
Analysis for the presence of acini composed of >10% pos-
itive cells reveals that BPH glands exhibited this criterion
in 50% (11/22) of the cases compared to 0/22 for the ade-
nocarcinmatous glands (figure 3). The average scoring for
the twenty-two cases (table 1) was also significantly lower
(P < 0.01) for the adenocarcinomatous glands (0.32) as
compared to the BPH glands (1.68); i.e. ~5-fold differ-
ence. Also, in every case in which the tissue sections
showed a positive score for BPH glands, the
adenocarcinomatous glands exhibited a lower score.
Thus, all the criteria consistently reveal that the immuno-
Table 1: ZIP1 immuno-positivity of glandular components in tissue sections of confirmed cases of prostate cancer.
Case no. Grade ZIP1 IHC scorea
Normal PIN BPH Malignant
1 3 +++ +++ Negative
23 ++ + +
3 1 Negative + Negative
4 2 + Negative
5 2 Negative Negative
6 1 Negative +++ Negative
72+ + ++
8 1 +++ +
9 1 ++ +++ Negative
10 2 +++ Negative
11 1 ++ Negative
12 2 Negative Negative
13 1 ++ +
14 1 + Negative
15 1 + Negative
16 1 Negative + Negative
17 2 +++ +
18 1 + ++ +
19 1 + Negative
20 1 + Negative
21 2 + +++ +
22 1 Negative Negative
NEG ZIP1 IHC 3/22 (14%) 15/22 (68%)*
SCORES > + 3/4 0/6 11/22 0/22*
MEAN SCOREb 1.75 0.6 1.68(1.09) 0.32(0.48)*
a Scoring of immunoreactivity was done as follows: negative, no positive cells; score +, <10% positive cells; score ++, 10–50% positive cells; score 
+++, >50% positive cells
b MEAN SCORE: MEAN(SD) for each group was obtained by the sum of the +'s/number of cases.
* P < 0.01; BPH VS MALIGNANT GROUPSMolecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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reactive ZIP1 is always reduced and mostly non-detectable
in the malignant glandular epithelium. Another impor-
tant observation is the absence of a correlation between
the stage of prostate cancer and the down regulation of
ZIP1. This reveals that the down regulation occurs early in
the malignant process and persists throughout its progres-
Immunohistochemical detection of ZIP1 transporter protein in malignant and nonmalignant loci of a representative prostate  cancer tissue section Figure 2
Immunohistochemical detection of ZIP1 transporter protein in malignant and nonmalignant loci of a representative prostate 
cancer tissue section. (A) BPH, magnification is 1000×, bar = 10 µm. (B) Normal, magnification is 400×, bar = 25 µm. (C) PIN, 
magnification is 400×, bars = 25 µm. (D) Adenocarcinoma, magnification 400×, bar = 10 µm Note the immuno-positivity of the 
plasma membrane of BPH and normal glands. The malignant and PIN loci show no detectable ZIP1 so that the plasma mem-
brane of these cells is not visible.Molecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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sion in the primary site; which is consistent with the early
changes in zinc levels.
As would be expected, the presence of normal peripheral
zone glands in the malignant tissue sections is minimal,
and insufficient for statistical analysis. However in three
of the 4 cases, the normal glands exhibited the expected
higher ZIP1 expression than the adenocarcinomatous
glands, and gave results that were similar to BPH; both of
which are zinc accumulating glands. In one case the nor-
mal gland was negative for ZIP1, which, seemingly, is an
anomaly. However an important point needs to be con-
sidered. It is consistent with existing evidence (discussed
below) that these metabolic changes occur before the
appearance of histopathological evidence of malignant
cells. Therefore, this "anomaly" might be due to changes
that occur in a "premalignant" neoplastic condition that
was histologically identified as "normal". Furthermore, in
all five cases with PIN, the glands were either negative or
+ (none was ++ or +++), which mimics the profile of the
adenocarcinomatous glands. It is striking that the com-
bined PIN and adenocarcinoma glands showed no
instance of ZIP1 positive cells that exceeded 10%. This
could be supportive of a malignant relationship between
PIN and adenocarcinoma; but further studies with
additional PIN and normal peripheral zone glands are
needed. Nevertheless, the Roswell Park study clearly
establishes a consistent down-regulation of hZIP1 trans-
porter in malignant prostate glands that corroborates and
extends the results of the U.Maryland study, and is further
corroborated by the following ClaflinU study.
In a parallel study (unpublished information, to be pre-
sented in a separate report), the tissue sections were also
assayed for the immunohistochemical identification of
m-aconitase. m-Aconitase was prevalent and unchanged
in BPH, malignant, PIN and normal glands. Thus the
down regulation of ZIP1 is specific. Moreover, the differ-
ences in citrate levels in malignant versus non malignant
glands is not due to altered levels of m-aconitase. This re-
emphasizes the role of altered zinc and ZIP1 in the meta-
bolic transformation associated with prostate malignancy.
The ClaflinU Study (AK-D, OB)
In this study, ZIP1 mRNA expression (RT-in situ-PCR)
and the relative level of zinc content were determined in
the normal peripheral zone glands versus malignant
glands from 38 prostate resections. The typical results rep-
resented in Figure 4 were consistently observed in all 38
prostate resections. The results show that hZIP1gene
expression is evident uniformly in the epithelium of the
normal peripheral zone glands; and is absent in the
stroma. hZIP1 expression is markedly down regulated to
the extent of not being demonstrable in the adenocarcino-
matous glands; and presents the same appearance as the
surrounding stroma. Of significance is the apparent down
regulation of ZIP1 in early-stage as well as in advanced-
stage malignant glands; which is consistent with the
decrease in ZIP1 transporter protein shown in the Roswell
Park study.
Correspondingly, Figure 4 shows the high level of cellular
zinc that characterizes the normal glandular epithelial
cells (green color). In contrast, the stroma exhibits a low
level of zinc. Therefore, the in situ zinc staining provides
the expected differential in zinc between normal glandu-
lar epithelium and stroma. The marked reduction of cellu-
lar zinc in the epithelium of the adenocarcinomatous
glands is apparent. Like the expression of ZIP1, the loss of
zinc occurs early in malignancy. Due to the depletion of
zinc in the malignant glands, the stromal zinc level gives
the appearance of relatively higher zinc levels. Many stud-
ies have observed that zinc levels are greatly decreased in
extracts of resected malignant tissue preparations. How-
ever, the ClaflinU study provides the first in situ detection
of the depleted cellular zinc levels in adenocarcinomatous
glands as compared to the high zinc levels in normal glan-
dular epithelium. An important revelation is that the
decrease in zinc level in the malignant glands is due to a
decrease in the cellular accumulation of zinc. This
Comparative results of ZIP1 immuno-positive glands of tissue  sections from subjects described in Table 1 Figure 3
Comparative results of ZIP1 immuno-positive glands of tissue 
sections from subjects described in Table 1. A. Summary of 
glands that exhibited a positive Zip1 reactivity. The number 
of cases is shown in each bar. B. The number of cases in 
which the glandular epithelium contained cells that exhibited 
a ZIP1 score >+ (more than 10% of the cells comprising the 
acini). The differences in A and B between BPH glands and 
adenocarcinomatous glands are significant, P < 0.01.Molecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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In situ detection of ZIP1 mRNA and zinc levels in normal and malignant glands Figure 4
In situ detection of ZIP1 mRNA and zinc levels in normal and malignant glands. Panel A. Representative ZIP1 mRNA in 
Prostate Sections . Sections (inserts 1,2) from two prostate cancer subjects are shown with low magnification. Blue arrows 
point to acini with normal glandular epithelium that exhibit ZIP1 mRNA. White arrows point to adenocarcinomatous glands in 
which ZIP1 expression is not demonstrable. Insert 3 is a higher magnification of a section from a cancer patient to show more 
detail. Blue arrows point to acini with normal glandular epithelium. Red arrows point to malignant glands. Green arrows point 
to stromal (fibromuscular) tissue. The malignant epithelial cells exhibit a complete absence of detectable ZIP1 mRNA in the 
glandular epithelium. The normal glandular epithelium exhibits ZIP1 expression; and no ZIP1 expression in the stroma. Normal 
acini marked 'a' show uniform ZIP1 mRNA expression in the glandular epithelium. Advanced adenocarcinomatous glands 
marked as 'b" show uniform absence of ZIP1 mRNA. Developing early stage adenocarcinomatous glands marked 'c' show a 
progression of normal ZIP1 expressing cells and malignant cells that lost the expression of ZIP1. Panel B. Representative 
Zinc Levels in Prostate Sections. High zinc is represented by Newport Green yellow stain and low zinc is represented by 
TSQ red stain. The malignant region of the peripheral zone shows a significant depletion of zinc in the malignant glandular epi-
thelium as exhibited by the red staining (white arrows). The depletion of zinc is evident in early differentiated malignant glands 
as represented by combinations of red and yellow staining in the glandular epithelial cells. As malignancy advances to the undif-
ferentiated stage, the zinc is further depleted as represented by the dominant red stain and no yellow stain in the glandular epi-
thelium of the adenocarcinomatous glands. The depletion of zinc in the malignant glandular region results in the surrounding 
stroma showing a higher zinc level (green stain) than the glandular epithelium. In contrast, the normal peripheral zone glands 
exhibit high zinc levels as represented by the uniform yellow stain and absence of red stain in the glandular epithelium. The 
stroma surrounding the glands exhibits a lower zinc level as shown by the red stain.Molecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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establishes that the decrease in intracellular zinc, and not
impaired secretion of zinc into the lumen (prostatic
fluid), is principally responsible for the decrease in malig-
nant tissue zinc level. Thus, the results of the ClaflinU
study are consistent with and corroborate the Roswell
Park study and the preliminary results of the UMaryland
study.
Discussion
The Zinc-Citrate Connection in Normal and Malignant 
Prostate
The results of the present study coupled with the numer-
ous and consistent reports of others [[4-8,12-14] for
reviews], provide direct overwhelming clinical and exper-
imental evidence that, in prostate cancer, the lost ability of
the malignant cells to accumulate zinc is a consistent
event in the development of malignancy. However, the
significance and further corroboration of this relationship
requires the understanding and recognition of the unique
role of zinc in normal prostate function and in prostate
cancer. The major function of the human prostate gland
peripheral zone (as in other animals) is the production
and secretion of enormously high levels of citrate; which
we refer to as "net citrate production". This capability of
the normal secretory epithelial cells is the result of their
unique ability to accumulate high levels of zinc; which
inhibit m-aconitase activity and citrate oxidation [20,21].
Thus, one must recognize that the production and accu-
mulation of citrate is dependent upon and is preceded by
the accumulation of zinc in the glandular epithelial cells.
Therefore, changes in the level of citrate in the peripheral
zone are the result of and indicative of changes in zinc lev-
els. The recent development of in situ magnetic resonance
spectroscopy of prostate citrate levels in normal periph-
eral zone and malignant loci conclusively establishes that
citrate levels are always greatly reduced in malignancy [see
reviews [22-24]]. The consistency of this citrate relation-
ship now makes magnetic resonance spectroscopy imag-
ing (MRSI) of the prostate gland the most effective and
reliable procedure for the identification, localization and
volume estimation of malignant loci in the peripheral
zone. Data collected from virtually all the existing MRSI
reported studies reveal that there exists no case in which
the malignant loci retain the high citrate levels of the nor-
mal peripheral zone glands as represented in figure
5[13,22]. These citrate changes revealed by magnetic reso-
nance spectroscopy provide indirect evidence of corre-
sponding changes in the accumulation of zinc, which is
the cause of the changes in citrate. This is further verified
by the comparative changes in zinc shown in figure 5. The
profile of direct measurements of zinc changes associated
with malignant prostate tissue strikingly replicates the cit-
rate profile. This is evident despite the fact that these are
different studies with different subjects and different
stages of cancer. These relationships provide compelling
evidence that, in prostate cancer, the malignant cells lose
the ability to accumulate high zinc levels; and malignant
cells that retain the accumulation of high zinc levels virtu-
ally never exist.
The Concept of the Role of hZIP1 and Zinc in Prostate 
Cancer
The existence of the zinc and citrate relationships in nor-
mal prostate and prostate cancer is irrefutable. How these
relationships are involved as factors in the development
and progression of prostate malignancy is important to
understanding the pathogenesis of prostate cancer. It is
well documented that all tumor cells undergo metabolic
Composite of zinc and citrate levels in prostate Figure 5
Composite of zinc and citrate levels in prostate. The zinc 
data are taken from Zaichick et al [9] and show the range of 
zinc levels in resected prostate tissue samples from different 
subjects. The citrate data are taken from Kurhanewicz et al 
[41] and show the range of citrate levels as determined by in 
situ magnetic resonance spectroscopy imaging of the pros-
tate gland of different subjects. The actual zinc and citrate 
concentrations for normal were set to 100 and the values for 
BPH and PCa were adjusted accordingly. Note the parallel-
isms in that zinc and citrate levels are consistently signifi-
cantly low in malignancy; and that no case exists in which the 
malignant loci retain the high zinc or high citrate levels that 
characterize normal or hypertrophic glands. The values 
above each bar are the number of subjects.Molecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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transformations that are essential for their malignant
existence (25, 26 for reviews). It is important to empha-
size that these metabolic transformations are not the
cause of malignancy. Malignancy requires the genetic
transformation of a sane cell to a neoplastic cell that is
endowed with the potential capability of malignancy. The
metabolic transformation is essential for the neoplastic
cells to manifest their malignant capabilities.
The accumulation of zinc in normal prostate glandular
epithelial cells results in two important effects; a meta-
bolic effect and a proliferative effect. Its metabolic effect is
the inhibition of citrate oxidation that is essential for the
prostate function of production and secretion of high lev-
els of citrate [20,21]; and its inhibition of terminal oxida-
tion [27]. This has a bioenergetic cost in that the
inhibition of citrate oxidation results in a ~60% loss of
ATP production that would arise from complete glucose
oxidation. Consequently, zinc-accumulating citrate-pro-
ducing cells (normal peripheral zone epithelial cells) are
energy-inefficient cells. A second effect of zinc is its inhi-
bition of prostate cell proliferation. This effect results
from zinc induction of apoptosis in prostate cells [28-31].
These are the consequences imposed upon highly special-
ized zinc-accumulating citrate-producing cells (i.e. nor-
mal peripheral zone secretory epithelial cells) in order to
achieve their unique function of net citrate production.
Malignant prostate cells do not exist for the specialized
function of citrate production and secretion. They must
replace the metabolic pathways associated with net citrate
production with metabolic relationships that are suitable
for their malignant existence. That the malignant prostate
cells in situ never exist as zinc-accumulating, citrate-pro-
ducing cells is evidence of the incompatibility of the high
zinc accumulation and net citrate production for their
existence. Their metabolic transformation to energy-effi-
cient citrate-oxidizing cells that have lost the ability to
accumulate zinc provides their metabolic/bioenergetic
requirements of malignancy. Also, the apoptotic influence
of zinc is eliminated, which permits the proliferation of
the malignant cells. However, the evidence presented
herein clearly establishes hZIP1 down regulation in the
primary in situ site and further suggests that this is the
explanation for the consistently observed decrease in zinc
levels in prostate cancer.
This concept is represented in figure 6. The occurrence of
this metabolic transformation is dependent upon the
ability of the normal epithelial cells and the inability of
the malignant cells to accumulate zinc. The present
The integrated role of ZIP1, zinc, and citrate metabolism in the pathogenesis of prostate malignancy Figure 6
The integrated role of ZIP1, zinc, and citrate metabolism in the pathogenesis of prostate malignancy. The normal glandular epi-
thelial cell expresses ZIP1 that permits zinc accumulation, which inhibits citrate oxidation and terminal respiration. Citrate 
accumulates and coupled ATP production is reduced. A genetic transformation results in a neoplastic cell with potential malig-
nant capability. ZIP1 expression is silenced by epigenetic factors which eliminate Zip1 transporter and accumulation of zinc in 
the premalignant cell. The level of cellular zinc decreases which removes the inhibitory effects on citrate oxidation and terminal 
oxidation. The Krebs cycle is functional and coupled ATP production is increased. The malignant cell is metabolically and 
bioenergetically capable of manifesting its malignant potential. Additionally, the growth inhibitory effect of zinc is removed, 
which allows growth and progression of the malignant cell.Molecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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studies establish that hZIP1 is down-regulated in the ade-
nocarcinomatous glands. This is consistent with the
down-regulation of hZIP1 gene expression in the African-
American male population, which exhibits a higher inci-
dence of prostate cancer [18]. The functional importance
of hZIP1 in the accumulation of zinc in prostate cells has
been established [15-17]. Over-expression of hZIP1
results in increased accumulation of zinc which leads to
inhibition of cell proliferation; whereas cells with down-
regulation of hZIP1 have decreased cellular zinc levels and
increased proliferation. Also the accumulation of zinc in
the malignant prostate cells in culture and in vivo [31]
results in increased citrate levels.
Consequently, consistent clinical and experimental evi-
dence strongly implicate the down-regulation of hZIP1 in
the lost ability of the malignant cells to accumulate zinc.
The existence of hZIP1 insures that prostate cells will accu-
mulate zinc. If ZIP1 is not down regulated in the neoplas-
tic cell, zinc accumulation and its metabolic/energetic and
apoptotic effects will prevail; and the neoplastic cell will
remain in a pre-malignant dormant state and/or will die.
In this concept (figure 6), prostate malignancy requires
two essential transformations; the genetic transformation
to a neoplastic cell with potential malignant capability;
and the metabolic transformation to an energy-efficient
citrate-producing cell that has lost the ability to accumu-
late zinc. These relationships provide a plausible explana-
tion and expectation for the apparent absence of the
identification of malignant prostate glands that exhibit
high zinc and high citrate levels.
The present studies raise two related important issues that
we will be investigating: what is the cause of the down reg-
ulation of ZIP1? ; do the ZIP1 and zinc changes persist in
the metastatic cells in situ? No information currently
exists regarding the latter issue. The fact that hZIP1 is
expressed in prostate cancer cell lines (that were estab-
lished from metastatic lesions) suggests that down regula-
tion of hZIP1 is a reversible phenomenon that occurs in
the primary site in situ. This is suggestive of an epigenetic
effect imposed by the interaction of the neoplastic cells
and their in situ environment. In this case, the in vitro
conditions of the cultured cells would eliminate the in
situ factor(s) associated with the suppression of hZIP1
expression; thus permitting its re-expression. Moreover,
the re-expression in the culture cells results in functional
hZIP1 that manifests zinc uptake ; so that a fatal mutation
is not involved. It is notable that SLC5A8, a gene that
encodes a monocarboxylic acid transporter protein, has
been reported to be a tumor suppressor gene in colon can-
cer [32-35] and other cancers [36,37]. The silencing of
that gene occurs by hypermethylation and is a common
and early event in human colon cancer. Similarly, it is
plausible to propose that hZIP1 is a candidate tumor sup-
pressor gene in prostate cancer. It will be important to
determine the in situ conditions and mechanism that ini-
tiates the silencing of ZIP1 gene expression; which will
then provide an understanding of the etiology of prostate
malignancy.
The focus of this report on ZIP1 is not to imply that other
zinc transport processes might not be involved in the
altered accumulation of zinc. Rishi et al [18] demon-
strated that ZIP1 and also ZIP2 are expressed in human
prostate glandular epithelium. An increase in export of
zinc could also decrease zinc accumulation by "true"
malignant cells. However no information currently exists
concerning the functional role of zinc exporters in pros-
tate cells. Beck et al [38] reported that ZnT-4 was
decreased in peripheral zone malignant tissue when com-
pared to normal peripheral zone tissue samples. ZnT-4 is
associated with the sequestering of cytosolic zinc into
organelles, and is not involved as a plasma membrane
zinc exporter. Moreover, a decrease in ZnT-4 would not be
associated with a decrease in cellular zinc level, even as a
secretory process. They also reported that ZnT-1 expres-
sion was unchanged in malignant versus normal periph-
eral zone. ZnT-1 does function as a plasma membrane-
associated zinc exporter in some cells and possibly in
prostate cells. Hasumi et al [39] reported that ZnT-1
expression was significantly lower in malignant prostate
tissue samples when compared to BPH samples, which
led them to conclude that ZnT-1 was not likely to be asso-
ciated with the decreased zinc accumulation in the malig-
nant cells. Consequently, a possible role of altered
expression of zinc exporters in the genetic/metabolic
transformation of the malignant cells in situ is not evi-
dent, but more research is required regarding this issue.
We are now investigating the possible involvement of
other zinc transporters in prostate malignancy.
Conclusion
The present studies, conducted independently in three
institutions, collectively establish the presence of hZIP1
gene expression, the presence of membrane-associated
hZIP1 transporter protein, and the accumulation of cellu-
lar zinc in the normal peripheral zone glandular epithe-
lium and in benign hyperplastic glandular epithelium.
The studies reveal that hZIP1 gene expression is down-reg-
ulated and hZIP1 transporter protein is depleted in aden-
ocarcinomatous glands in prostate cancer.
Correspondingly, the cellular level of zinc is also depleted.
These effects occur in early and late stages of malignant
development of the peripheral zone. hZIP1 expression is
evident in the malignant prostate cell lines in culture. This
leads to the likelihood that the lost expression in the ade-
nocarcinomatous glands is due to an epigenetic silencing
of hZIP1 that occurs in the in situ environment of the
peripheral zone. When coupled with the voluminousMolecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
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clinical and experimental evidence, it becomes irrefutable
that the development of malignancy in prostate cancer
involves an essential metabolic transformation that
results in the lost ability of malignant cells to accumulate
zinc. Conversely, as long as the capability of high zinc
accumulation exists, the neoplastic cells cannot manifest
their malignant potential. Consequently, the expression
of hZIP1 that sustains zinc accumulation in prostate cells
will prevent the malignant activities and proliferation of
the neoplastic cells. This provides a compelling basis for
the proposal that hZIP1 down regulation is necessary for
tumor progression and could be a tumor suppressor gene
in prostate cancer. Consideration of all the clinical and
experimental evidence leads to the concept that zinc and
citrate-related metabolism play an important role in the
pathogenesis and progression of prostate malignancy.
Methods
1. U.Maryland Study
Immunohistochemistry of Human Tissue Sections
Paraffin mounted serial sections of human prostate tissue
was used for hZIP1 immunohistochemistry staining.
Hematoxylin and eosin staining was used for identifica-
tion of normal and adenocarcinomatous glands. For
immunohistochemistry, slides were dewaxed by incuba-
tion in xylene and then rehydrated. Non-specific binding
of antibody was blocked by incubation in BlokHen (Aves
Labs, Inc.) solution. The slides were washed with PBS,
incubated in hZIP1 antibody solution, washed again, and
incubated with fluorescein-labeled secondary antibody
solution; and then washed and mounted with anti-fade
fluorescent medium (Molecular Probes). For control
staining, adjacent serial sections were stained as described
above except that the antibody-depleted and preimmune
preparation were used instead of antihZIP1 antibody
Immunocytochemistry of Prostate Cells
PC-3 and LNCaP cells were plated on cover slips. The
cover slips were washed with PBS, and the cells fixed in
paraformaldehyde solution. The cells were permeabilized
by incubation in 0.2% NP-40 solution, washed in PBS,
and stained by the procedure described above for
immunohistochemistry.
RT-PCR of Human Tissue mRNA
hZIP and GAPDH cDNA were synthesized from total
mRNA isolated from human prostate tissue using 1.0 ug
of total RNA, reverse transcriptase and random primers
(TaqMan7 reagents, Perkin Elmer). hZIP1 and GAPDH
fragments were amplified from the cDNA using 1.0 µM
forward and reverse primers and 35 cycles. These condi-
tions were shown to be in the quantitative detection range
based on the concentration of template DNA. The cloned
cDNA for hZIP1 was used as the template DNA in control
reactions to determine the specificity of the PCR reactions.
The RT-PCR products were analyzed by agarose gel
electrophoresis with ethidium bromide staining and pho-
tographed under UV light. No products were detected
without reverse transcriptase. The primers for hZIP1 were
5'-TCAGAGCCTCCAGTGCCTGT-3' and 5'-GCAGCAG-
GTCCAGGAGACAA-3'
2. The Roswell Park Study
Immunohistochemistry of Human Tissue Sections
Embedded prostatic adenocarcinoma slides that con-
tained both benign prostatic hyperplasia (BPH) and ade-
nocarcinomatous foci were obtained from Roswell Park
Cancer Institute. Normal glands and intra epithelial neo-
plastic foci (PIN) were seen in a few cases. Immunohisto-
chemistry with anti-hZIP1 antibody was performed by
standard protocol [40]. Briefly, the slides were deparaffin-
ized. Antigen retrieval was done by heating in 10 mM
sodium citrate buffer (pH 6.0) at 98°C, incubated in 1%
hydrogen peroxide (H2O2), blocked with 5% BlokHen
with avidin D, incubated with ZIP1 antibody in 5%
BlokHen with biotin (Vector Laboratories) at 4°C over
night followed by incubation with Horseradish peroxi-
dase-labeled goat anti chicken IgY secondary antibody in
a dilution of 1:200 (AvesLabs, Tigard, Oregon). Color was
developed by incubating slides with DAB kit (Vector Lab-
oratories) followed by Hematoxylin counterstaining. Sec-
tions were examined with light E600 Nikon microscope.
Pictures were taken with Spot advanced soft ware (ver-
sion. 4.0.1). The appearance of membrane-associated
hZIP1 immuno-positivity of the glandular epithelial cells
was used for scoring as previously described [40]. The
scores employed were; negative, no positive cells; + <10%
positive cells; ++ 10–50% positive cells; +++ > 50% posi-
tive cells. The mean scores between groups were analyzed
by the Student's t-Test.
3. The ClaflinU. Study
RT-in situ-PCR of Human Tissue Sections
Fresh frozen sections from 38 post-prostatectomy of men
with clinical histories of prostate cancer were processed
for zinc content analyses and RT-in situ-PCR. RT-in situ-
PCR of the frozen sections was performed as described in
detail by Rishi et al [18]. To preserve the intensity of the
hybridized probes, the tissues were not counter-stained.
Parallel hematoxylin and eosin-stained slides were used to
identify various histologic cell types in the tissue sections.
Microscopic examination usually reveals cytoplasmic
staining for mRNA versus nuclear staining for DNA. Cell
enumeration was performed on coded slides by at least
two pathologists.
Determination of Intracellular Zinc Content
The relative intracellular zinc content in situ was deter-
mined by utilizing fresh frozen tissues. For this purpose
the cells must be biochemically active. The relativeMolecular Cancer 2005, 4:32 http://www.molecular-cancer.com/content/4/1/32
Page 12 of 13
(page number not for citation purposes)
concentrations of zinc in various cell types of the prostatic
tissues were determined according to the manufacturer's
instructions (Molecular Probes, Inc., Eugene, Oregon,
USA). Briefly, the frozen tissues were incubated with
equal molar concentrations of two zinc-indicator dyes;
Newport Green (NPG), and TSQ. The frozen tissues were
incubated in 20 ul/section of the zinc indicator cocktail
over night and washed in PBS, gently, without disturbing
the tissues. The slides were heat-fixed for 10 sec at 104°C
to immobilize the signals. These slides were mounted
with solution containing 50% glycerol in PBS and
observed under a fluorescent microscope. TSQ has a high
affinity for zinc (Kd~10 nM) and a detection limit of ~0.1
nM. The ZN-TSQ positive cells stain red. NPG has moder-
ate zinc-binding affinity (Kd ~1 µM). The ZN-NPG posi-
tive cells appear yellowish green. Together, TSQ and NPG
provide a relative difference in zinc concentrations in var-
ious cell types of the prostate. TSQ has about 2–3-log
higher affinity for zinc than NPG, but has detection limit
of about 3-log lower than NPG. Therefore, the cells that
contain very low concentrations of intracellular zinc
appear red and the ones with higher concentrations
appear green. The cells with no detectable Zn2+ will
appear black or dark blue.
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